[go: up one dir, main page]

PT2366393E - Roflumilaste para o tratamento da hipertensão pulmonar - Google Patents

Roflumilaste para o tratamento da hipertensão pulmonar

Info

Publication number
PT2366393E
PT2366393E PT111687646T PT11168764T PT2366393E PT 2366393 E PT2366393 E PT 2366393E PT 111687646 T PT111687646 T PT 111687646T PT 11168764 T PT11168764 T PT 11168764T PT 2366393 E PT2366393 E PT 2366393E
Authority
PT
Portugal
Prior art keywords
roflumilast
treatment
pulmonary hypertension
oxide
pharmaceutically acceptable
Prior art date
Application number
PT111687646T
Other languages
English (en)
Inventor
Rolf Beume
Christian Schudt
Armin Hatzelmann
Degenhard Marx
Hermann Tenor
Saadia Eddahibi
Serge Adnot
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Publication of PT2366393E publication Critical patent/PT2366393E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PT111687646T 2005-04-19 2006-04-12 Roflumilaste para o tratamento da hipertensão pulmonar PT2366393E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05103147 2005-04-19

Publications (1)

Publication Number Publication Date
PT2366393E true PT2366393E (pt) 2013-10-04

Family

ID=34939388

Family Applications (1)

Application Number Title Priority Date Filing Date
PT111687646T PT2366393E (pt) 2005-04-19 2006-04-12 Roflumilaste para o tratamento da hipertensão pulmonar

Country Status (24)

Country Link
US (1) US8648100B2 (pt)
EP (2) EP1874309A1 (pt)
JP (2) JP2008536888A (pt)
KR (1) KR101358479B1 (pt)
CN (2) CN102614176A (pt)
AU (1) AU2006237300B2 (pt)
BR (1) BRPI0610498A2 (pt)
CA (1) CA2604295C (pt)
CY (1) CY1114468T1 (pt)
DK (1) DK2366393T3 (pt)
EA (1) EA016037B1 (pt)
ES (1) ES2433661T3 (pt)
HR (1) HRP20130982T1 (pt)
IL (2) IL186538A0 (pt)
ME (1) ME01609B (pt)
MX (1) MX2007012711A (pt)
NO (1) NO20075662L (pt)
NZ (1) NZ561746A (pt)
PL (1) PL2366393T3 (pt)
PT (1) PT2366393E (pt)
RS (1) RS52944B (pt)
SI (1) SI2366393T1 (pt)
WO (1) WO2006111495A1 (pt)
ZA (1) ZA200707930B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009013286A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Organic compounds
WO2009115235A1 (en) * 2008-03-20 2009-09-24 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of pulmonary hypertension
SG11201505835QA (en) 2013-01-28 2015-08-28 Incozen Therapeutics Pvt Ltd Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CN107038965A (zh) * 2017-05-05 2017-08-11 深圳浩翔光电技术有限公司 Led显示装置、成型模组、及其生产工艺
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
KR20190005708A (ko) * 2017-07-05 2019-01-16 이화여자대학교 산학협력단 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물
BR112022015104A2 (pt) * 2020-01-31 2022-09-27 Arcutis Biotherapeutics Inc Método para melhorar a distribuição e estender a meia-vida plasmática de uma composição de roflumilaste e uso de uma composição
CN115969847A (zh) * 2023-02-03 2023-04-18 华中科技大学 罗氟司特在制备治疗心力衰竭的药物中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB371800A (en) 1929-10-21 1932-04-28 Willem Zaadnoordijk A process of filtering gases and fogs
GB343664A (en) 1929-12-27 1931-02-26 William Duncan Grant Subaquatic rock drilling devices
GB357903A (en) 1931-01-05 1931-10-01 Oskar Rosenfelder Improvements in catamenial appliances and infants' diapers
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
RU2137754C1 (ru) 1993-07-02 1999-09-20 Бик Гульден Ломберг Хемише Фабрик ГмбХ Фторалкоксизамещенные бензамиды, способ их получения и фармацевтическая композиция на их основе
US5728705A (en) 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
AU6823098A (en) * 1997-02-28 1998-09-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists
KR100441229B1 (ko) 1997-04-25 2004-07-22 화이자 인코포레이티드 타입 5 시클릭 구아노신 3',5'-모노포스페이트 포스포디에스테라제(ｃＧＭＰ ＰＤＥ5)를 억제하는 성기능 장애 치료용 피라졸로피리미디논
FR2762841B1 (fr) 1997-04-30 1999-07-02 Jouveinal Inst Rech Diazepino-indolones inhibitrices de phosphodiesterases iv
IL135462A0 (en) 1997-11-12 2001-05-20 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
HUP0102543A3 (en) 1998-04-20 2002-01-28 Pfizer Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction and medicaments containing them
DE19819023A1 (de) 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidine
TWI223598B (en) 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
WO2000056719A1 (en) 1999-03-22 2000-09-28 Bristol-Myers Squibb Company FUSED PYRIDOPYRIDAZINE INHIBITORS OF cGMP PHOSPHODIESTERASE
AU767558B2 (en) 1999-09-16 2003-11-13 Mitsubishi Tanabe Pharma Corporation Aromatic nitrogenous six-membered ring compounds
TWI224966B (en) 1999-11-02 2004-12-11 Pfizer Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
PL365443A1 (en) * 2001-01-31 2005-01-10 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
SK8942003A3 (en) 2001-01-31 2004-10-05 Pfizer Prod Inc Ether derivatives useful as inhibitors
US6973229B1 (en) * 2001-02-28 2005-12-06 Lambda Opticalsystems Corporation Node architecture for modularized and reconfigurable optical networks, and methods and apparatus therefor
DE10135815A1 (de) 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
BR0213683A (pt) * 2001-11-05 2004-10-26 Merck Patent Gmbh Hidrazono-malonitrilas
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
WO2003097050A2 (en) * 2002-05-16 2003-11-27 Pharmacia Corporation A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
WO2004072079A1 (en) 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
CA2520779A1 (en) * 2003-03-31 2004-11-11 Kyowa Hakko Kogyo Co., Ltd. Agent for intra-airway administration
JP2006528229A (ja) * 2003-05-22 2006-12-14 アルタナ　ファルマ　アクチエンゲゼルシャフト Ｐｄｅ４阻害剤及びｐｄｅ５阻害剤を含有する組成物
WO2004105751A1 (en) 2003-05-28 2004-12-09 Glaxo Group Limited Traitement of cardiovascular pathology
US7132435B2 (en) * 2003-07-25 2006-11-07 Pfizer Inc. Compounds
US7153870B2 (en) * 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
GB0317498D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Compounds
EP1658060A2 (en) 2003-08-22 2006-05-24 Boehringer Ingelheim Pharmaceuticals Inc. Methods of treating copd and pulmonary hypertension
CA2563377A1 (en) 2004-04-23 2005-11-03 Celgene Corporation Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension

Also Published As

Publication number Publication date
JP2013237683A (ja) 2013-11-28
ME01609B (me) 2014-09-20
IL186538A0 (en) 2008-06-05
ES2433661T3 (es) 2013-12-12
IL218745A0 (en) 2012-05-31
NO20075662L (no) 2007-11-07
MX2007012711A (es) 2008-01-11
US20090215836A1 (en) 2009-08-27
CN102614176A (zh) 2012-08-01
EP2366393A3 (en) 2011-09-28
EP2366393B1 (en) 2013-08-07
SI2366393T1 (sl) 2013-12-31
WO2006111495A1 (en) 2006-10-26
KR20080002950A (ko) 2008-01-04
ZA200707930B (en) 2008-05-28
AU2006237300B2 (en) 2011-10-13
EA200702201A1 (ru) 2008-04-28
CY1114468T1 (el) 2017-01-25
US8648100B2 (en) 2014-02-11
EA016037B1 (ru) 2012-01-30
KR101358479B1 (ko) 2014-02-06
RS52944B (sr) 2014-02-28
EP1874309A1 (en) 2008-01-09
CA2604295C (en) 2014-10-07
BRPI0610498A2 (pt) 2010-06-22
CA2604295A1 (en) 2006-10-26
EP2366393A2 (en) 2011-09-21
PL2366393T3 (pl) 2014-01-31
CN101163476A (zh) 2008-04-16
AU2006237300A1 (en) 2006-10-26
NZ561746A (en) 2011-09-30
HRP20130982T1 (hr) 2013-11-22
JP2008536888A (ja) 2008-09-11
DK2366393T3 (da) 2013-10-21

Similar Documents

Publication Publication Date Title
NO2024010I1 (no) Gefapixant, or a pharmaceutically acceptable salt thereof
LTC1830843I2 (lt) Indolidono dariniai, skirti fibrozinių ligų gydymui arba prevencijai
TW200734311A (en) New compounds
WO2005007192A3 (en) Cytoprotection through the use of hif hydroxylase inhibitors
PT2385053E (pt) Intermediários para a preparação de compostos bicíclicos condensados como inibidores mtor
ZA200606049B (en) Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral disease
ZA200706697B (en) 3, 4-Substituted pyrrolidine derivatives for the treatment of hypertension
WO2007058583A3 (en) Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies
WO2006124713A3 (en) 4-biarylyl-1-phenylazetidin-2-ones
SI1855677T1 (sl) 3,11 b-cis-dihidrotetrabenazin za zdravljenje shizofrenije in drugih psihoz
IL186748A0 (en) 4 - phenyl - 5 - oxo 1, 4, 5, 6, 7, 8 - hexahydroquinoline derivatives for the treatment of infertility
PT2056805E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
ZA200709094B (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
ZA200805028B (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
PT2366393E (pt) Roflumilaste para o tratamento da hipertensão pulmonar
WO2007103584A3 (en) Polyamides for treating human papilloma virus
ZA200709096B (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility
TW200744567A (en) Phenylethylamine analogs and their use for treating glaucoma
WO2009018551A3 (en) Therapeutic compounds
ZA200800999B (en) Use of N-dibenz (b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy
ITCE20040004A1 (it) Pneumocestello per la cattura dei calcoli del coledoco.
IL186457A0 (en) Process for the preparation of 9,10-dehydro-12,13-desoxyepothilone derivatives
PL1961423T3 (pl) Zastosowanie pneumocytów typu II w leczeniu chorób płuc związanych z zwłóknieniem płuc
PL1600446T3 (pl) Nowe pochodne 3,3-dimetylo-5-cyjano-benzoksepin użyteczne do otrzymywania pochodnych 5-formylo-benzoksepin